Amphastar Pharmaceuticals Inc ( (AMPH) ) has released its Q4 earnings. Here is a breakdown of the information Amphastar Pharmaceuticals Inc presented to its investors.
Amphastar Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development, manufacturing, and marketing of generic and proprietary injectable, inhalation, and intranasal products, with a focus on hospital and urgent care settings. Amphastar Pharmaceuticals reported net revenues of $186.5 million for the fourth quarter of 2024, with a GAAP net income of $38.0 million and an adjusted non-GAAP net income of $47.2 million. For the full year, the company achieved net revenues of $732.0 million, a GAAP net income of $159.5 million, and an adjusted non-GAAP net income of $200.8 million. Key highlights include the successful achievement of over $100 million in annual sales for Primatene MIST® and strong growth in BAQSIMI® sales. The company also noted a decrease in sales for some products due to competition and market shifts. Looking ahead, Amphastar plans to continue expanding its product pipeline and growing its proprietary brands, with a focus on maintaining strong sales performance and developing new products.